Morgan Stanley
VOR icon

Morgan Stanley’s Vor Biopharma VOR Stock Holding History

Morgan Stanley’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
61,561
-55,160
-47% -$835K ﹤0.01% 5150
2026
Q1 		$2.08M Buy
116,721
+88,258
+310% +$1.24M ﹤0.01% 4742
2025
Q4 		$372K Buy
28,463
+24,007
+539% +$447K ﹤0.01% 5667
2025
Q3 		$217K Buy
4,456
+4,431
+17,724% +$178K ﹤0.01% 5858
2025
Q2 		$815 Sell
25
-1,747
-99% -$15.4K ﹤0.01% 7353
2025
Q1 		$25.4K Sell
1,772
-6,224
-78% -$149K ﹤0.01% 6476
2024
Q4 		$178K Buy
7,996
+6,774
+554% +$112K ﹤0.01% 5835
2024
Q3 		$17.1K Sell
1,222
-7,243
-86% -$132K ﹤0.01% 6548
2024
Q2 		$169K Buy
8,465
+2,130
+34% +$68.9K ﹤0.01% 5748
2024
Q1 		$300K Sell
6,335
-2,268
-26% -$99.6K ﹤0.01% 5560
2023
Q4 		$387K Buy
8,603
+4,752
+123% +$196K ﹤0.01% 5422
2023
Q3 		$163K Buy
3,851
+1,540
+67% +$83.5K ﹤0.01% 5673
2023
Q2 		$143K Sell
2,311
-1,163
-33% -$106K ﹤0.01% 5794
2023
Q1 		$374K Buy
3,474
+2,626
+310% +$291K ﹤0.01% 5420
2022
Q4 		$113K Buy
848
+464
+121% +$45.9K ﹤0.01% 5928
2022
Q3 		$30K Sell
384
-1,130
-75% -$111K ﹤0.01% 6627
2022
Q2 		$150K Buy
1,514
+1,008
+199% +$103K ﹤0.01% 6037
2022
Q1 		$60K Buy
506
+44
+10% +$7.49K ﹤0.01% 6623
2021
Q4 		$108K Sell
462
-2,119
-82% -$611K ﹤0.01% 6396
2021
Q3 		$809K Sell
2,581
-3,042
-54% -$904K ﹤0.01% 5188
2021
Q2 		$2.1M Buy
+5,623
New +$2.77M ﹤0.01% 4594

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley's VOR Position: Q2 2026 in Review

Morgan Stanley reduced its Vor Biopharma (VOR) stake by 47% in Q2 2026, selling an estimated $835K and leaving 61,561 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5150.

Morgan Stanley first reported a position in VOR in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.1M in Q2 2021. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Morgan Stanley held 61,561 shares of Vor Biopharma worth $1.13M as of Q2 2026.
  • Morgan Stanley sold 55,160 Vor Biopharma shares in Q2 2026, an estimated $835K.
  • Vor Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5150 holding.
  • Morgan Stanley first reported a position in Vor Biopharma in Q2 2021 and has held it in 21 quarters since.
  • Morgan Stanley's Vor Biopharma position peaked at $2.1M in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.